Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...9899100101102103104105106107108...136137»
  • ||||||||||  Journal:  AChR-and MuSK-positive myasthenia gravis: Double trouble. (Pubmed Central) -  Dec 16, 2020   
    At the detection of double positive AChR and MuSK Abs, the treating physician often feels unsecure about the optimal treatment strategy and the long-term prognosis. The detailed clinical record and the long observation of these rare cases, are mandatory for best management in clinical practice.
  • ||||||||||  Clinical, Journal:  Comment on CoVID-19 in patients with myasthenia gravis. (Pubmed Central) -  Dec 16, 2020   
    The detailed clinical record and the long observation of these rare cases, are mandatory for best management in clinical practice. No abstract available
  • ||||||||||  rifampicin / Generic mfg.
    IgG4-Related Symptomatic Abdominal Aortic Aneurysm in a Patient with Known Myasthenia Gravis () -  Dec 16, 2020 - Abstract #SAVS2021SAVS_69;    
    Similar imaging and macroscopic findings between IgG4-related and infectious AAA have led to open repair in reported cases followed by histologic diagnosis. Ongoing research is directed at finding a non-invasive marker of disease to allow for early treatment with anti-inflammatory therapies to reduce rupture risk and help guide the type of surgical intervention offered to these patients.
  • ||||||||||  Clinical, Journal:  Comment on COVID-19 in patients with myasthenia gravis: Author response. (Pubmed Central) -  Dec 16, 2020   
    Ongoing research is directed at finding a non-invasive marker of disease to allow for early treatment with anti-inflammatory therapies to reduce rupture risk and help guide the type of surgical intervention offered to these patients. No abstract available
  • ||||||||||  Review, Journal:  Update on Neurological Manifestations of SARS-CoV-2. (Pubmed Central) -  Dec 16, 2020   
    Peripheral nervous system effects such as hyposmia, hypogeusia, ophthalmoparesis, Guillain-Barré syndrome, and motor peripheral neuropathy have also been reported. In this review, we update the clinical manifestations of COVID-19 concentrating on the neurological associations that have been described, including broad ranges in both central and peripheral nervous systems.
  • ||||||||||  Clinical, Journal:  A case of anti-MuSK positive MG with recurrent right-sided heart failure as the initial manifestation (Pubmed Central) -  Dec 15, 2020   
    Selective plasma exchange did not produce a satisfactory therapeutic effect, and she received additional intravenous immunoglobulin, plasmapheresis, and oral immunosuppressive therapy after which she was successfully weaned off the ventilator. This case report highlights the following points: (a) Recurrent right-sided congestive heart failure may be the first manifestation of anti-MuSK Ab-positive MG and, (b) detection of the anti-MuSK Ab alone is a convincing rationale to diagnose patients with MG.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma
    Journal:  Amifampridine to treat Lambert-Eaton myasthenic syndrome. (Pubmed Central) -  Dec 15, 2020   
    The recommended dose is 80 mg a day, divided 3 or 4 times a day. Side effects are usually mild, and the most frequently reported are paresthesia.
  • ||||||||||  mycophenolate mofetil / Generic mfg., azathioprine / Generic mfg.
    Trial completion date, Trial primary completion date, HEOR:  PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov) -  Dec 14, 2020   
    P=N/A,  N=220, Recruiting, 
    No abstract available Trial completion date: Nov 2020 --> Jan 2021 | Trial primary completion date: Nov 2020 --> Jan 2021
  • ||||||||||  Journal:  Superior Vena Cava Resection in Locally Advanced Thymoma-Surgical and Survival Outcomes. (Pubmed Central) -  Dec 12, 2020   
    Superior vena cava resection and reconstruction is a feasible and oncologically superior option in invasive thymoma with SVC involvement. This challenging surgical procedure should only be attempted by an experienced team of thoracic and cardiac surgeons at high-volume centre to achieve best outcomes.
  • ||||||||||  Clinical, Journal:  Survival Outcomes in Patients with Thymoma after Thymectomy in an Indian Scenario. (Pubmed Central) -  Dec 12, 2020   
    Masaoka stage, WHO histologic type, completeness of surgery, and local recurrence did affect the survival significantly. Masaoka stages III and IV, histological type B3, incomplete resection during surgery, and presence of local recurrence did independently predict a worse overall survival.
  • ||||||||||  Journal, Checkpoint inhibition:  Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. (Pubmed Central) -  Dec 12, 2020   
    In summary, immune checkpoint inhibitor-associated myopathy is a distinct, treatable immune-mediated myopathy with common ocular involvement, frequent lymphopenia and necrotizing histopathology, which contrary to immune-mediated necrotizing myopathy, is featured by clusters of necrotic fibres and not accompanied by anti-hydroxy-3-methylglutaryl-CoA reductase or signal recognition particle antibodies. Normal or mildly elevated creatine kinase level does not exclude the diagnosis.
  • ||||||||||  Budding association between gut microbiome in the development of Myasthenia Gravis () -  Dec 12, 2020 - Abstract #IDDF2020IDDF_153;    
    Conclusions These findings provide vital insight and knowledge on MG gut microbiome that could enhance the potential for future microbial-based therapies to improve the clinical outcome of MG. Figure 1 illustrates the dysbiosis of the gut microbiome in myasthenia gravis patients.
  • ||||||||||  Review, Journal:  Minimal Access Surgery for Thymoma. (Pubmed Central) -  Dec 8, 2020   
    There is however significant evidence now available for the use of minimally invasive approaches for early-stage thymomas. This article aims to discuss the various minimally invasive approaches currently being employed for thymomas.
  • ||||||||||  Clinical, Journal:  Concentric Needle Jitter in 97 Myasthenia Gravis Patients. (Pubmed Central) -  Dec 8, 2020   
    There was a high jitter abnormality in generalized myasthenia gravis cases with one muscle tested, with about a 2% increase in sensitivity when a second is added. Concentric needle electrode jitter had high sensitivity similar to the single fiber electrode (93.8%), followed by antibody titers (86.6%), and abnormal decrement (78.4%).
  • ||||||||||  Journal:  "Neurological manifestations of COVID-19" - guideline of the German society of neurology. (Pubmed Central) -  Dec 8, 2020   
    This S1 guideline provides guidance for the care of patients with SARS-CoV-2 infection regarding neurological manifestations, patients with neurological disease with and without SARS-CoV-2 infection, and for the protection of healthcare workers. This is an abbreviated version of the guideline issued by the German Neurological society and published in the Guideline repository of the AWMF (Working Group of Scientific Medical Societies; Arbeitsgemeinschaft wissenschaftlicher Medizinischer Fachgesellschaften).
  • ||||||||||  Rystiggo (rozanolixizumab) / UCB
    Trial completion date, Trial primary completion date:  A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Dec 4, 2020   
    P3,  N=276, Enrolling by invitation, 
    This is an abbreviated version of the guideline issued by the German Neurological society and published in the Guideline repository of the AWMF (Working Group of Scientific Medical Societies; Arbeitsgemeinschaft wissenschaftlicher Medizinischer Fachgesellschaften). Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Dec 2020 --> May 2021
  • ||||||||||  Review, Journal:  Practical approach to respiratory emergencies in neurological diseases. (Pubmed Central) -  Dec 3, 2020   
    A tailored assistance may include manual and mechanical cough assistance, noninvasive ventilation, endotracheal intubation, invasive mechanical ventilation, or tracheotomy. This review provides practical recommendations for prevention, recognition, management, and treatment of respiratory emergencies in neurological diseases, mostly in teenagers and adults, according to type and severity of baseline disease.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] IgLON5 syndrome: clinical characterization of a large European cohort () -  Nov 28, 2020 - Abstract #DGN2020DGN_395;    
    The heterogeneous presentation of the IgLON5 syndrome complicates the diagnosis and thus delays the initiation of therapy. In particular, the recording of sleep-associated symptoms (e.g. sleep attacks and sleep breathing disorders) appears relevant.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg.
    Journal:  Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. (Pubmed Central) -  Nov 25, 2020   
    The symptomatic improvement with CYC was noted within the 1st month. We conclude that CYC is effective as an induction to remission therapy, although our data suggest it is not effective as a long-term therapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition:  Myositis as a neuromuscular complication of immune checkpoint inhibitors. (Pubmed Central) -  Nov 25, 2020   
    The IgG positivity suggests a local role of the ICI in the pathophysiology of the myositis. Further research must be performed to identify patients at risk and to optimize treatment of the complications.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date:  Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity (clinicaltrials.gov) -  Nov 23, 2020   
    P=N/A,  N=114, Completed, 
    Practitioners should be aware of the potential risks of CSA when administering IVIg for MG patients, in particular in old patients with vascular risk factors. Recruiting --> Completed | N=600 --> 114 | Trial completion date: Mar 2021 --> Nov 2020
  • ||||||||||  Journal:  Congenital myasthenic syndrome due to a TOR1AIP1 mutation: a new disease pathway for impaired synaptic transmission. (Pubmed Central) -  Nov 22, 2020   
    Following these findings, electromyography was performed on cases of other nuclear envelopathies caused by mutations in LaminA/C or emerin, but decrement on repetitive nerve stimulation or other indications of defective neuromuscular transmission were not seen. Thus, this report highlights the first nuclear membrane protein in which defective function can lead to impaired synaptic transmission.
  • ||||||||||  Clinical, Journal:  Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report. (Pubmed Central) -  Nov 22, 2020   
    It is important to recognize that myasthenia gravis patients may represent a uniquely vulnerable population that requires enhanced surveillance and screening to prevent significant morbidity and mortality. This case describes how even a mild infection with no significant clinical sequelae or significant signs on imaging studied can precipitate a crisis event.